The European Medicines Agency advised AEterna Zentaris Inc. (Nasdaq: AEZS) that the Phase III study of its cancer treatment perifosine is acceptable. Shares of the drug development company gained 27 cents to close at $1.65.
EMA Advises AEterna Zentaris
April 15, 2010 at 18:31 PM EDT
